316 related articles for article (PubMed ID: 23505226)
1. High-throughput proteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome.
Anitua E; Prado R; Azkargorta M; Rodriguez-Suárez E; Iloro I; Casado-Vela J; Elortza F; Orive G
J Tissue Eng Regen Med; 2015 Nov; 9(11):E1-12. PubMed ID: 23505226
[TBL] [Abstract][Full Text] [Related]
2. Morphogen and proinflammatory cytokine release kinetics from PRGF-Endoret fibrin scaffolds: evaluation of the effect of leukocyte inclusion.
Anitua E; Zalduendo MM; Prado R; Alkhraisat MH; Orive G
J Biomed Mater Res A; 2015 Mar; 103(3):1011-20. PubMed ID: 24890049
[TBL] [Abstract][Full Text] [Related]
3. Perspectives and challenges in regenerative medicine using plasma rich in growth factors.
Anitua E; Alkhraisat MH; Orive G
J Control Release; 2012 Jan; 157(1):29-38. PubMed ID: 21763737
[TBL] [Abstract][Full Text] [Related]
4. A novel personalized 3D injectable protein scaffold for regenerative medicine.
Anitua E; Pino A; Troya M; Jaén P; Orive G
J Mater Sci Mater Med; 2017 Dec; 29(1):7. PubMed ID: 29243192
[TBL] [Abstract][Full Text] [Related]
5. Potential of endogenous regenerative technology for in situ regenerative medicine.
Anitua E; Sánchez M; Orive G
Adv Drug Deliv Rev; 2010 Jun; 62(7-8):741-52. PubMed ID: 20102730
[TBL] [Abstract][Full Text] [Related]
6. Release kinetics of platelet-derived and plasma-derived growth factors from autologous plasma rich in growth factors.
Anitua E; Zalduendo MM; Alkhraisat MH; Orive G
Ann Anat; 2013 Oct; 195(5):461-6. PubMed ID: 23722041
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial.
Madurantakam P; Yoganarasimha S; Hasan FK
J Vis Exp; 2015 Sep; (103):. PubMed ID: 26485642
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization and clinical use of platelet-rich plasma-derived Endoret-Gel as an autologous treatment for atrophic scars.
García C; Pino A; Jimenez N; Truchuelo M; Jaén P; Anitua E
J Cosmet Dermatol; 2020 Jul; 19(7):1607-1613. PubMed ID: 31709744
[TBL] [Abstract][Full Text] [Related]
9. Autologous fibrin scaffolds: When platelet- and plasma-derived biomolecules meet fibrin.
Anitua E; Nurden P; Prado R; Nurden AT; Padilla S
Biomaterials; 2019 Feb; 192():440-460. PubMed ID: 30500725
[TBL] [Abstract][Full Text] [Related]
10. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF).
Dohan Ehrenfest DM; Bielecki T; Jimbo R; Barbé G; Del Corso M; Inchingolo F; Sammartino G
Curr Pharm Biotechnol; 2012 Jun; 13(7):1145-52. PubMed ID: 21740377
[TBL] [Abstract][Full Text] [Related]
11. Identification of protein fragments as pattern features in MALDI-MS analyses of serum.
Zimmerman LJ; Wernke GR; Caprioli RM; Liebler DC
J Proteome Res; 2005; 4(5):1672-80. PubMed ID: 16212420
[TBL] [Abstract][Full Text] [Related]
12. Platelet-rich plasma to improve the bio-functionality of biomaterials.
Anitua E; Tejero R; Alkhraisat MH; Orive G
BioDrugs; 2013 Apr; 27(2):97-111. PubMed ID: 23329397
[TBL] [Abstract][Full Text] [Related]
13. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation.
Anitua E; Sanchez M; Merayo-Lloves J; De la Fuente M; Muruzabal F; Orive G
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6066-73. PubMed ID: 21613374
[TBL] [Abstract][Full Text] [Related]
14. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project.
Li X; Gong Y; Wang Y; Wu S; Cai Y; He P; Lu Z; Ying W; Zhang Y; Jiao L; He H; Zhang Z; He F; Zhao X; Qian X
Proteomics; 2005 Aug; 5(13):3423-41. PubMed ID: 16052619
[TBL] [Abstract][Full Text] [Related]
15. The effects of plasma rich in growth factors (PRGF-Endoret) on healing of medial collateral ligament of the knee.
Yoshioka T; Kanamori A; Washio T; Aoto K; Uemura K; Sakane M; Ochiai N
Knee Surg Sports Traumatol Arthrosc; 2013 Aug; 21(8):1763-9. PubMed ID: 22527414
[TBL] [Abstract][Full Text] [Related]
16. Autologous liquid platelet rich fibrin: A novel drug delivery system.
Miron RJ; Zhang Y
Acta Biomater; 2018 Jul; 75():35-51. PubMed ID: 29772345
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a more physiological plasma rich in growth factor (PRGF) protocol: Anticoagulant removal and reduction in activator concentration.
Anitua E; Prado R; Troya M; Zalduendo M; de la Fuente M; Pino A; Muruzabal F; Orive G
Platelets; 2016 Jul; 27(5):459-66. PubMed ID: 26940906
[TBL] [Abstract][Full Text] [Related]
18. Fibrin as a scaffold for cardiac tissue engineering.
Barsotti MC; Felice F; Balbarini A; Di Stefano R
Biotechnol Appl Biochem; 2011; 58(5):301-10. PubMed ID: 21995533
[TBL] [Abstract][Full Text] [Related]
19. Differential profile of protein expression on human keratocytes treated with autologous serum and plasma rich in growth factors (PRGF).
Anitua E; de la Fuente M; Muruzabal F; Sánchez-Ávila RM; Merayo-Lloves J; Azkargorta M; Elortza F; Orive G
PLoS One; 2018; 13(10):e0205073. PubMed ID: 30312303
[TBL] [Abstract][Full Text] [Related]
20. Cellular composition modifies the biological properties and stability of platelet rich plasma membranes for tissue engineering.
Anitua E; Zalduendo M; Troya M; Tierno R; Alkhraisat MH
J Biomed Mater Res A; 2023 Nov; 111(11):1710-1721. PubMed ID: 37318048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
